Medication-assisted Treatment (MAT) Market Share

  • Report ID: 5814
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Medication-assisted Treatment (MAT) Market Share

North American Market Forecast

Medication-assisted Treatment market in the North America region is anticipated to hold the largest share of about 45% by the end of 2036. The regional growth is attributed to the factor that government, healthcare, organizations, and philanthropic entities in the region have allocated increased funding and resources to support MAT initiatives. This financial backing has enabled the expansion of treatment facilities, training programs, and public awareness campaigns. According to the National Institute on Drug Abuse, methadone treatment, including medication and integrated psychosocial & medical support services cost USD 6, 55, 20 per year in the US. In addition, the region has recognized the importance of MAT in treating opioid addiction and regulatory frameworks have been adapted to facilitate the integration of MAT into mainstream healthcare, ensuring better access to these treatments for individuals in need and stimulate the market in the region.

European Market Analysis

The Europe medication-assisted treatment market is estimated to the second largest revenue share of about 30% by the end of 2036. The market’s expansion can be attributed to the multidisciplinary approach adopted by the European healthcare system to deal with substance disorders. MAT is integrated into this approach, combining medications with counseling and psychosocial support to address the complex nature of substance use disorders comprehensively. In addition, Community-based MAT programs have been established in various European regions. For example, a Harm reduction program encompasses interventions and policies that seek to mitigate the health, social, and economic harms of drug use to individuals, communities, and societies.  These initiatives focus on providing localized and accessible treatment options, emphasizing the importance of community involvement and support in the recovery process which further stimulate the medication-assisted treatment market in the region.

Research Nester
Medication-assisted Treatment Market size
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5814
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increase in substance abuse deaths, rising awareness of Medical –assisted Treatment (MAT) and emergence of technological innovations are the major factors driving the growth of the medication-assisted treatment market.

The market size of medication-assisted treatment is anticipated to attain a CAGR of 11.4% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Orexo AB, Novartis AG, Mylan N.V., Lupin Limited, Hikma Pharmaceuticals PLC and others.

The drug type segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample